Patents Assigned to National Institute of Health
-
Patent number: 11872394Abstract: Described herein are systems and methods for the treatment of pain using electrical nerve conduction block (ENCB). Contrary to other methods of pain treatment, the ENCB can establish a direct block of neural activity, thereby eliminating the pain. Additionally, the ENCB can be administered without causing electrochemical damage. An example method can include: placing at least one electrode contact in electrical communication with a region of a subject's spinal cord; applying an electrical nerve conduction block (ENCB) to a nerve in the region through the at least one electrode contact; and blocking neural activity with the ENCB to reduce the pain or other unwanted sensation in the subject.Type: GrantFiled: May 13, 2021Date of Patent: January 16, 2024Assignees: CASE WESTERN RESERVE UNIVERAITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Niloy Bhadra, Narendra Bhadra, Kevin L Kilgore, Scott Lempka, Jesse Wainright, Tina Vrabec, Manfred Franke
-
Patent number: 11845955Abstract: The present disclosure relates to a simple, fast, and low cost method for 3D microvascular imaging, termed “scatter labeled imaging of microvasculature in excised tissue” (SLIME). The method can include perfusing a contrast agent through vasculature of a tissue sample. The contrast agent can include colloids and a dispersant. After the contrast agent is perfused through the vasculature, the vasculature of the tissue sample can be treated with a molecule that cross links with at least a portion of the dispersant to form a sticky, non-Newtonian polymer that prevents leakage of the contrast agent out of the vasculature of the tissue sample. The tissue sample can then be immersed in a solution comprising a clearing agent and subsequently imaged.Type: GrantFiled: August 1, 2022Date of Patent: December 19, 2023Assignees: CASE WESTERN RESERVE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Michael W. Jenkins, Yehe Liu
-
Patent number: 11771749Abstract: The present disclosure provides compositions and methods of eliciting an anti-tumor immune response and treating cancer comprising at least one peptide of KRAS.Type: GrantFiled: February 5, 2018Date of Patent: October 3, 2023Assignees: The Medical College of Wisconsin, Inc., National Institutes of Health (NIH)Inventors: Jing Pan, Ming You, Ronald Lubet
-
Publication number: 20230241144Abstract: Pharmaceutical preparations, Chinese herbal preparations, foods, and other compositions may contain, as an active ingredient, an ephedra extract, an ephedrine-alkaloid-free ephedra extract, or a polymercondensed tannin derived from an ephedra extract. Such compositions may be useful for preventing or treating COVID-19 infection (COVID-19). Such compositions are preferably provided in an orally ingestible form.Type: ApplicationFiled: October 1, 2021Publication date: August 3, 2023Applicants: THE KITASATO INSTITUTE, JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES, Matsuyama University, TOKIWA PHYTOCHEMICAL CO., LTD., TSUMURA & CO.Inventors: Toshihiko HANAWA, Sumiko HYUGA, Hiroshi ODAGUCHI, Yukihiro GODA, Masashi HYUGA, Masashi UEMA, Hiroshi ASAKURA, Nahoko UCHIYAMA, Yoshiaki AMAKURA, Morio YOSHIMURA, Jinwei YANG, Kazushige MIZOGUCHI
-
Patent number: 11708612Abstract: Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.Type: GrantFiled: December 2, 2020Date of Patent: July 25, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Andrea Bild, Jason I. Griffiths
-
Patent number: 11701361Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.Type: GrantFiled: January 7, 2019Date of Patent: July 18, 2023Assignees: NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John Cambier, Elizabeth Franks
-
Publication number: 20230203101Abstract: The present invention relates to a recombinant spike protein of the COVID-19 virus forming a trimer and a method for mass-producing the recombinant spike protein, and more specifically to a method for designing a recombinant gene expressing a recombinant spike protein of the COVID-19 virus forming a trimer for the purposes of enhancing immunogenicity and effective antigen delivery, and a method for mass-producing the recombinant spike protein in plants.Type: ApplicationFiled: April 22, 2021Publication date: June 29, 2023Applicants: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KOREA NATIONAL INSTITUTE OF HEALTH, BIOAPPLICATIONS INCInventors: In Hwan HWANG, Shijian SONG, Rezaul Islam Khan MD, Haiping DIAO, Eun Ju SOHN, Bo Hwa CHOI, Jang Hoon CHOI, Eun Young JANG, Young Jae LEE
-
Patent number: 11666569Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: May 14, 2020Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENTInventors: Sergio A. Gradilone, Nicholas F. LaRusso
-
Publication number: 20230146286Abstract: Biomarkers for diagnosing the disease activity, disease severity or disease type of severe cutaneous adverse drug reactions (SCARs) such as drug-induced hypersensitivity syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis are provided. Also provided is a method of testing SCARs, comprising measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in a sample derived from a subject.Type: ApplicationFiled: April 15, 2021Publication date: May 11, 2023Applicants: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES, TOSOH CORPORATIONInventors: Yoshiro SAITO, Ryosuke NAKAMURA, Noriaki ARAKAWA, Yasuo OHNO, Takashi IZUMI, Motonobu SATO, Takayoshi NISHIYA, Michiko AIHARA
-
Patent number: 11627907Abstract: An intracellular monitoring device (IMD) that fits completely inside a living cell, and causes no significant impairment, to a cell's normal biological processes. The IMD monitors a cell for its level of a biological substance (e.g., calcium ion concentration) of interest. If the biological substance reaches or exceeds a threshold, the IMD transmits an electromagnetic signal, received by an antenna outside the cell. Each IMD has its electromagnetic signal encoded with a unique frequency. Detection of the frequency components, in the signals received by an antenna, permits identification of the source IMD's. A high calcium ion concentration is indicative of a strongly-activated cerebral cortex neuron. Brain tissue is relatively transparent to near infrared, making it a good frequency band, for the electromagnetic signals from neuron-monitoring IMD's. The near infrared of each IMD can be produced by quantum dots, powered by bioelectric catalysis triggered by high calcium ion concentration.Type: GrantFiled: June 24, 2019Date of Patent: April 18, 2023Assignees: National Institutes of Health, Office of Technology Transfer, Galiana Technology Inc.Inventors: Bruce T Hope, Mark A Wells, Gregory D Sutton
-
Patent number: 11612619Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.Type: GrantFiled: November 1, 2019Date of Patent: March 28, 2023Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventors: Richard Eric Honkanen, Brandon Marshall D'Arcy, Mark Raymond Swingle
-
Patent number: 11555818Abstract: The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.Type: GrantFiled: May 14, 2019Date of Patent: January 17, 2023Assignee: The USA, as represted by the Secretary, Dept. of and Human Services, National Institutes of HealthInventors: Majda Haznadar, Ewy Mathe, Andrew D. Patterson, Curtis Craig Harris, Frank Gonzalez, Kristopher Krausz, Soumen Manna
-
Patent number: 11505559Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: October 30, 2018Date of Patent: November 22, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, YALE UNIVERSITYInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov, Vasilis Vasiliou
-
Publication number: 20220334121Abstract: Among the various aspects of the present disclosure is the provision of methods for detecting cancer in Neurofibromatosis Type 1 (NF1) patients.Type: ApplicationFiled: January 27, 2022Publication date: October 20, 2022Applicants: Washington University, NATIONAL INSTITUTES OF HEALTHInventors: Aadel Chaudhuri, Paul Jones, Jeffrey Szymanski, Angela Hirbe, Russell Sundby, John Shern
-
Patent number: 11474097Abstract: A cell-based quantitative high-throughput screening assay to monitor the formation of PFK1-mEGFP clusters by the action of small molecules to identify small molecules that promote intracellular PFK1 clustering in a cell cycle-dependent manner and may be used to treat cancer.Type: GrantFiled: June 26, 2019Date of Patent: October 18, 2022Assignees: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY, NATIONAL INSTITUTES OF HEALTHInventors: Songon An, Danielle L. Schmitt, James Inglese, Patricia Dranchak
-
Publication number: 20220299523Abstract: A highly sensitive allergen measurement method is provided. A method for detecting an allergen in a sample, comprising: treating a sample with a protease; and detecting presence or absence of an allergen marker in the enzyme-treated sample by analysis that utilizes chromatographic separation. The allergen comprises buckwheat and wheat.Type: ApplicationFiled: July 9, 2020Publication date: September 22, 2022Applicants: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES, NISSHIN SEIFUN GROUP INC.Inventors: Hiroshi AKIYAMA, Hiroyuki KIKUCHI, Yusuke SEKI, Chisato ARIMOTO
-
Publication number: 20220175986Abstract: Disclosed herein is a method for decontaminating an object to be treated by reducing the activity of endotoxin in a simple manner. The decontamination method includes a step (a) of irradiating an object to be treated with ultraviolet light of a wavelength of less than 200 nm to reduce activity of endotoxin attached to the object to be treated.Type: ApplicationFiled: March 11, 2020Publication date: June 9, 2022Applicants: Ushio Denki Kabushiki Kaisha, Director General of National Institute of Health SciencesInventors: Hiroko MATSUMOTO, Makoto YAMANAKA, Fumitoshi TAKEMOTO, Kenji HATAKEYAMA, Yuji HAISHIMA, Yukiko KUDO, Yutaka KIKUCHI, Chie FUKUI
-
Patent number: 11351185Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.Type: GrantFiled: March 11, 2020Date of Patent: June 7, 2022Assignees: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Enhong Jiang, Zhengping Zhuang, Jing Cui
-
Patent number: 11337753Abstract: The disclosure provides various embodiments of systems to facilitate the cutting of luminal tissue structures percutaneously.Type: GrantFiled: January 13, 2021Date of Patent: May 24, 2022Assignees: Telltale LLC, The National Institutes of Health (NIH)Inventors: Nasser Rafiee, Robert J Lederman, Rany Busold, Morgan House, Jaffar Khan, Toby Rogers, Christopher G Bruce
-
Publication number: 20220112179Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: December 20, 2021Publication date: April 14, 2022Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human Servi, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer